Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020019 · ClinicalTrials.gov registry record · Phase 2
Combined Pharmacotherapy for Cannabis Dependency
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT01020019: Completed Phase 2 study, sponsored by New York State Psychiatric Institute.
NCT01020019 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 156 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020019, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.
Interventions
- DRUG Placebo
- DRUG Dronabinol
- DRUG Lofexidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT01020019 record still lists
NCT01020019 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01020019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01020019 about?
NCT01020019 is a clinical study titled "Combined Pharmacotherapy for Cannabis Dependency". The purpose of this study is to see if Lofexidine in combination with Marinol is superior to placebo in achieving abstinence, reducing cannabis use and reducing withdrawal in cannabis-dependent patients seeking treatment for their marijuana use.
What is the current status of trial NCT01020019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2010-01. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01020019?
The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG), Lofexidine (DRUG).
Who is sponsoring clinical trial NCT01020019?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01020019's enrollment target sits among peer trials
156 445th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia